Patents by Inventor Arne Holmgren

Arne Holmgren has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11801262
    Abstract: Disclosed herein are antibiotic compositions, for example compositions that comprise a metal-containing agent and an organoselenium agent, and uses thereof.
    Type: Grant
    Filed: May 18, 2020
    Date of Patent: October 31, 2023
    Assignee: Thioredoxin Systems AB
    Inventors: Arne Holmgren, Jun Lu, Lili Zou
  • Patent number: 11013730
    Abstract: A method for treating a prokaryotic infection in an animal or human by administering a pharmaceutically acceptable composition, comprising administering a source of silver ions and a benzoisoselenazol derivative, e.g., an ebselen derivative.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: May 25, 2021
    Assignee: Thioredoxin Systems AB
    Inventors: Arne Holmgren, Jun Lu
  • Publication number: 20200281967
    Abstract: Disclosed herein are antibiotic compositions, for example compositions that comprise a metal-containing agent and an organoselenium agent, and uses thereof.
    Type: Application
    Filed: May 18, 2020
    Publication date: September 10, 2020
    Inventors: Arne Holmgren, Jun Lu, Lili Zou
  • Patent number: 10653717
    Abstract: Disclosed herein are antibiotic compositions, for example compositions that comprise a metal-containing agent and an organoselenium agent, and uses thereof.
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: May 19, 2020
    Inventors: Arne Holmgren, Jun Lu, Lili Zou
  • Publication number: 20190307726
    Abstract: Disclosed herein is glutathione in conjunction with an isoselenazol or isothiazol derivative, e.g., ebselen or ebsulfur derivative, to treat diabetes, lupus, or other chronic inflammatory disease. The glutathione is preferably provided in a rapid release oral formulation that presents the glutathione for absorption in the first part of the ileum. The isoselenazol or isothiazol derivative is preferably provided in a delayed release formulation to avoid overlapping high enteric concentration. These may be provided within the same unit dosage form.
    Type: Application
    Filed: November 23, 2016
    Publication date: October 10, 2019
    Inventors: Arne Holmgren, Harry B. Demopoulos, Kevin Davis
  • Patent number: 10058542
    Abstract: A method for treating a prokaryotic infection in an animal or human by administering a pharmaceutically acceptable composition, comprising administering a source of silver ions and a benzoisoselenazol derivative, e.g., an ebselen derivative.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: August 28, 2018
    Assignee: Thioredoxin Systems AB
    Inventors: Arne Holmgren, Jun Lu
  • Publication number: 20180185410
    Abstract: Disclosed herein are antibiotic compositions, for example compositions that comprise a metal-containing agent and an organoselenium agent, and uses thereof.
    Type: Application
    Filed: December 5, 2017
    Publication date: July 5, 2018
    Inventors: Arne Holmgren, Jun Lu, Lili Zou
  • Publication number: 20140088149
    Abstract: The mechanism of action of Ebselen differentiates between bacterial and mammalian thioredoxin reductase (TrxR). It displays fast oxidation of mammalian Trx and via the NADPH-TrxR catalyzed turnover of ebselen selenol with hydrogen peroxide, and therefore are mammalian antioxidants. Ebselen, and its diselenide, are strong competitive inhibitors of E. coli TrxR with Ki of 0.14 ?M and 0.46 ?M, respectively. E. coli mutants lacking glutathione reductase or glutathione were much more sensitive to inhibition by ebselen. Since either glutaredoxin or thioredoxin systems are electron donors to ribonucleotide reductase, ebselen targets primarily glutathione and glutaredoxin-negative bacteria, a class which includes major pathogens. Ebselen, and similar compounds are therefore useful as antibacterial agents, even for multiresistant strains.
    Type: Application
    Filed: November 25, 2013
    Publication date: March 27, 2014
    Inventors: Arne Holmgren, Jun Lu, Alexios Vlamis-Gardikas, Rong Zhao, Karuppasamy Kandasamy, Lars Engman, Lars Engstrand, Sven Hoffner
  • Patent number: 8592468
    Abstract: The mechanism of action of Ebselen differentiates between bacterial and mammalian thioredoxin reductase (TrxR). It displays fast oxidation of mammalian Trx and via the NADPH-TrxR catalyzed turnover of ebselen selenol with hydrogen peroxide, and therefore are mammalian antioxidants. Ebselen, and its diselenide, are strong competitive inhibitors of E. coli TrxR with Ki of 0.14 ?M and 0.46 ?M, respectively. E. coli mutants lacking glutathione reductase or glutathione were much more sensitive to inhibition by ebselen. Since either glutaredoxin or thioredoxin systems are electron donors to ribonucleotide reductase, ebselen targets primarily glutathione and glutaredoxin-negative bacteria, a class which includes major pathogens. Ebselen, and similar compounds are therefore useful as antibacterial agents, even for multiresistant strains.
    Type: Grant
    Filed: March 23, 2011
    Date of Patent: November 26, 2013
    Assignee: Thioredoxin Systems AB
    Inventors: Arne Holmgren, Jun Lu, Alexios Vlamis-Gardikas, Rong Zhao, Karuppasamy Kandasamy, Lars Engman, Lars Engstrand, Sven Hoffner
  • Publication number: 20110288130
    Abstract: The mechanism of action of Ebselen differentiates between bacterial and mammalian thioredoxin reductase (TrxR). It displays fast oxidation of mammalian Trx and via the NADPH-TrxR catalyzed turnover of ebselen selenol with hydrogen peroxide, and therefore are mammalian antioxidants. Ebselen, and its diselenide, are strong competitive inhibitors of E. coli TrxR with Ki of 0.14 ?M and 0.46 ?M, respectively. E. coli mutants lacking glutathione reductase or glutathione were much more sensitive to inhibition by ebselen. Since either glutaredoxin or thioredoxin systems are electron donors to ribonucleotide reductase, ebselen targets primarily glutathione and glutaredoxin-negative bacteria, a class which includes major pathogens. Ebselen, and similar compounds are therefore useful as antibacterial agents, even for multiresistant strains.
    Type: Application
    Filed: March 23, 2011
    Publication date: November 24, 2011
    Applicant: THIOREDOXIN SYSTEMS AB
    Inventors: Arne Holmgren, Jun Lu, Alexios Vlamis-Gardikas, Rong Zhao, K. Kandasamy, Lars Engman, Lars Engstrand, Sven Hoffner
  • Patent number: 7671211
    Abstract: A substrate for thioredoxin reductase which comprises a compound represented by the following general formula (I) or (I?): wherein R1 and R2 independently represent a hydrogen atom, a halogen atom, a trifluoromethyl group and the like; R3 represents an aryl group, an aromatic heterocyclic group and the like; R4 represents a hydrogen atom, a hydroxyl group, a —S-?-amino acid group and the like; R5 represents a hydrogen atom or a C1-C6 alkyl group; Y represents oxygen atom or sulfur atom; n represents an integer of from 0 to 5; and the selenium atom may be oxidized, whose example includes 2-phenyl-1,2-benzisoselenazol-3(2H)-one or a ring-opened form thereof. The substrate is reduced by thioredoxin reductase in the presence of NADPH and enhances peroxidase activity of thioredoxin reductase.
    Type: Grant
    Filed: March 31, 2000
    Date of Patent: March 2, 2010
    Inventors: Arne Holmgren, Marjan H. Amiri, Hiroyuki Masayasu
  • Publication number: 20090005422
    Abstract: The mechanism of action of Ebselen differentiates between bacterial and mammalian thioredoxin reductase (TrxR). It displays fast oxidation of mammalian Trx and via the NADPH-TrxR catalyzed turnover of ebselen selenol with hydrogen peroxide, and therefore are mammalian antioxidants. Ebselen, and its diselenide, are strong competitive inhibitors of E. coli TrxR with Ki of 0.14 ?M and 0.46 ?M, respectively. E. coli mutants lacking glutathione reductase or glutathione were much more sensitive to inhibition by ebselen. Since either glutaredoxin or thioredoxin systems are electron donors to ribonucleotide reductase, ebselen targets primarily glutathione and glutaredoxin-negative bacteria, a class which includes major pathogens. Ebselen, and similar compounds are therefore useful as antibacterial agents, even for multiresistant strains.
    Type: Application
    Filed: May 22, 2007
    Publication date: January 1, 2009
    Applicant: THIOREDOXIN SYSTEMS AB
    Inventors: Arne Holmgren, Jun Lu, Alexios Vlamis-Gardikas, Rong Zhao, K. Kandasamy, Lars Engman, Lars Engstrand, Sven Hoffner